On Friday, Tableau Software Inc (NYSE:DATA)’s shares declined -0.15% to $84.68.
Tableau Software (DATA) declared the general availability of Tableau 9.1, making it easier for people to analyze data from any source while in the office or on the go. New capabilities give people more ways to answer questions with data, an entirely new mobile experience, new options for connecting to data and easier security and authentication for the enterprise.
The Tableau Mobile App is completely redesigned to make it easier for people to find, interact with and manage content on the go. Offline Snapshots save favorite views that can be seen offline at any time.
Tableau continues to deliver on its mission to assist people see and understand data whether that data is on premises or in the cloud. Tableau 9.1 provides more connectivity options and opens up new opportunities to connect to any web data through the web data connector.
Tableau Software, Inc., together with its auxiliaries, provides business analytics software products in the United States, Canada, and internationally. The company offers Tableau Desktop, a self-service analytics environment that empowers people to access and analyze data independently; and Tableau Server, a business intelligence platform with data administration, scalability, and security to foster the sharing of data, in addition to improve the dissemination of information in an organization and promote improved decision-making.
Intel Corporation (NASDAQ:INTC)’s shares dropped -2.32% to $29.02.
To assist mitigate cybersecurity risks associated with connected automobiles while encouraging technological progression and innovation, Intel Corporation recently declared the establishment of the Automotive Security Review Board (ASRB). The board will encompass top security industry talent across the globe with particular areas of expertise in cyber-physical systems. The ASRB researchers will perform ongoing security tests and audits intended to codify best practices and design recommendations for advanced cybersecurity solutions and products to benefit the automobile industry and drivers. Intel also published the first version of its automotive cybersecurity best practices white paper, which the company will continue to update based on ASRB findings.
Gartner predicts that “by 2020, the number of connected passenger vehicles on the road in use will be about 150 million; 60% to 75% of them will be capable of consuming, creating and sharing Web-based data.”1 The transition to a more connected world is exciting and requires that cybersecurity be addressed.
Intel will provide the ASRB with its automotive advanced development platforms on which to conduct research. Findings will then be published publicly as part of an ongoing process. To motivate the ASRB researchers, Intel will award a new car2 to the member who provides the most noteworthy and impactful cybersecurity contribution that can be implemented on Intel’s automotive platform. All details related to the Intel development platform and areas of security audit focus will be offered at the inaugural ASRB meet-up next month. Interested security professionals wishing to request participation can find out more information at www.intel.com/automotive/asrb.
Intel Corporation designs, manufactures, and sells integrated digital technology platforms worldwide. It operates through PC Client Group, Data Center Group, Internet of Things Group, Mobile and Communications Group, Software and Services, and All Other segments.
At the end of Friday’s trade, AbbVie Inc (NYSE:ABBV)‘s shares surged 2.12% to $61.13.
AbbVie (ABBV), in cooperation with Neurocrine Biosciences, Inc. (NBIX), declared the completion of a Phase 2b clinical trial evaluating the safety and efficacy of elagolix alone or in combination with add-back therapy contrast to placebo. The trial was conducted in women with heavy menstrual bleeding (HMB) associated with uterine fibroids. Preliminary results showed that all of the elagolix treatment arms, with and without add-back therapy, reduced heavy menstrual bleeding as contrast to placebo (p
Uterine fibroids (also called leiomyomas or myomas) are noncancerous muscle tissue tumors of the uterus. Fibroids are most common in women aged 30-40 years but can occur at any age. They can range in size from nearly undetectable to bulky masses that can distort the uterus. Fibroids can be asymptomatic but in some women cause symptoms such as: longer, more frequent, or heavy menstrual bleeding; menstrual pain; vaginal bleeding at time other than menstruation; pain in the abdomen or lower back; pain during sex; difficulty urinating; frequent urination; constipation or rectal pain.
Among the most common adverse events (AEs) were hot flush, headache, nausea, and vomiting. Some AEs such as hot flush were more frequent in the elagolix only treatment arms as contrast to the placebo and elagolix with add-back therapy treatment arms. Reduction in bone mineral density associated with elagolix alone was attenuated when elagolix was co-administered with add-back therapy. Discontinuations due to AEs were slightly greater for the elagolix 600 mg once-daily (QD) treatment arms with and without add-back therapy as contrast to elagolix 300mg twice-daily (BID) treatment arms with and without add-back therapy.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, counting those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants.
SYSCO Corporation (NYSE:SYY), ended its Friday’s trading session with -0.28% loss, and closed at $39.41.
At its 2015 Investor Day, Sysco Corporation (SYY) senior executives presented a three-year planned business plan designed to improve the customer experience, enhance associate engagement and deliver strong financial results to drive shareholder value over time.
Sysco anticipates to achieve its new operating income and return on invested capital targets by accelerating local case growth, improving gross margins, leveraging its end-to-end supply chain, reducing administrative costs and generating more than $1 billion in free cash flow per year2.
Joining DeLaney in presenting the Sysco plan to investors were Tom Bene, executive vice president and president of foodservice operations; Scott Charlton, executive vice president, supply chain; Joel Grade, executive vice president and chief financial officer; and Wayne Shurts, executive vice president and chief technology officer.
Sysco Corporation, through its auxiliaries, markets and distributes a range of food and related products primarily to the foodservice or food-away-from-home industry. It distributes a line of frozen foods, such as meats, seafood, fully prepared entrees, fruits, vegetables, and desserts; a line of canned and dry foods; fresh meats and seafood; dairy products; beverage products; imported specialties; and fresh produce.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
